

Jonathan Kadouch - Abstract

<p><u>Presenting Author & Affiliation</u></p> <p>Kadouch, Jonathan, Dermatologist, ReSculpt Clinic, Amsterdam, The Netherlands</p>
<p><u>Co-Authors & Affiliations (if applicable):</u></p> <p>X</p>
<p><u>Title of Poster Presentation</u></p> <p>Treatment of submental fat with deoxycholic acid (Belkyra)</p>
<p><u>Abstract of your presentation</u></p> <p>Submental fullness is known to be associated with negative social and psychological perceptions by both oneself and others. Although submental fullness can be weight-associated, for many individuals it results from a genetic predisposition and thus can often be resistant to weight loss strategies such as diet and exercise.</p> <p>According to data from the American Society for Dermatologic Surgery (ASDS) 2016 73% of people said they are bothered by their double chin.</p> <p>Deoxycholic acid has recently been approved for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat. The product is a non-human, non-animal form of deoxycholic acid, a naturally-occurring molecule in the body that aids in the breakdown and absorption of dietary fat.</p> <p>Deoxycholic acid injection, a minimally invasive procedure for neck contouring, was effective and generally well tolerated in the private practice setting.</p>
<p><u>References</u></p> <ul style="list-style-type: none">• Ascher B, Fellman J and Monheit G. ATX-101 (deoxycholic acid for reduction of submental fat. <i>Expert Review of Clinical Pharmacology</i>. 2016; 9(9):1131-1143. DOI: 10.1080/17512433.2016.1215911. Accessed October 20, 2016.• American Society for Dermatologic Surgery (ASDS). 2016 ASDS Consumer Survey (7,322 consumers) on Cosmetic Dermatologic Procedures. April 2016.• Ascher B, et al Efficacy, patient-reported outcomes and safety profile of ATX-101 (deoxycholic acid), an injectable drug for the reduction of unwanted submental fat: results from a phase III, randomized, placebo-controlled study. <i>Journal of the European Academy of Dermatology and Venereology</i>. 2014; 28(12)• BELKYRA® Summary of Product Characteristics.• Jones DH <i>et al</i>. REFINE-1, a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Trial with ATX-101, an Injectable Drug for Submental Fat Reduction. <i>Dermatol Surg</i>. 2016;42:38-49 DOI: 10:1097/DSS.0000000000000578.